MAR Polypill Phase 2 Alzheimer's Trial (NCT06597058)

Overview

Overview

NCT06597058 is a double-blind, placebo-controlled Phase 2 estimation study evaluating the efficacy and safety of a fixed-dose combination polypill (MAR Active 0.6g tablet) in subjects with Alzheimer's Disease. Sponsored by Noah Pharmaceuticals, Inc., the trial enrolled 103 participants and is designed to estimate treatment effect across multiple cognitive and functional endpoints["@nct06597058"].

The MAR polypill represents a multi-target, combination therapy approach to Alzheimer's disease — combining multiple pharmacological agents in a single tablet to address the multifactorial pathophysiology of AD. This strategy differs from single-target monoclonal antibody approaches (like [lecanemab](/clinical-trials/lecanemab-phase-3) or [donanemab](/clinical-trials/donanemab-trailblazer-alz2)) by targeting multiple disease pathways simultaneously through synergistic drug combinations["@polypill_concept"].

The polypill approach is grounded in the understanding that Alzheimer's disease involves multiple interconnected pathophysiological mechanisms — including amyloid accumulation, tau pathology, neurotransmitter deficits, neuroinflammation, and metabolic dysfunction — and that addressing these simultaneously may produce greater clinical benefit than targeting a single pathway["@ad_polypill_history"].

Trial Information

| Field | Value |
|-------|-------|
| NCT Number | NCT06597058 |
| Title | A Double-Blind, Placebo-Controlled Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill Administered to Subjects With Alzheimer's Disease |
| Phase | Phase 2 |
| Status | Recruiting / Active |
| Sponsor | Noah Pharmaceuticals, Inc. |
| Intervention | MAR Active 0.6g tablet (experimental) vs MAR Placebo 0.6g tablet |
| Participants | 103 (estimated) |
| Age Range | 50-85 years |
| Condition | Alzheimer's Disease (very mild to severe) |
| Study Design | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled, parallel-group |
| Start Date | October 16, 2024 |
| Primary Completion | December 31, 2025 (estimated) |
| Study Completion | February 15, 2026 (estimated) |

Scientific Rationale

The Polypill Concept in Neurodegeneration

The polypill strategy — combining multiple approved drugs in a single formulation — originated in cardiovascular medicine, where fixed-dose combination pills have demonstrated significant improvements in adherence and outcomes for hypertension, dyslipidemia, and secondary prevention[@polypill_cardiovascular]. The translation of this approach to Alzheimer's disease reflects growing recognition that AD is a multifactorial disease requiring multi-target intervention[@multifactorial_ad].

Key Rationale for the Polypill Approach in AD:

Comparison with Other AD Therapeutic Approaches

| Approach | Examples | Mechanism | Advantages | Limitations |
|----------|----------|-----------|------------|-------------|
| Anti-amyloid mAbs | Lecanemab, Donanemab | Remove amyloid plaques | Disease-modifying, biomarker evidence | ARIA risk, IV administration, cost |
| Cholinesterase inhibitors | Donepezil, Rivastigmine | Boost acetylcholine | Oral, well-established | Symptomatic only |
| Polypill/Multi-target | MAR (NCT06597058) | Multiple pathways | Synergistic, oral, repurposed agents | Unproven in AD, complexity |
| Symptomatic agents | Memantine, Exelon | Various | Symptomatic benefit | Do not modify disease |

Noah Pharmaceuticals

Noah Pharmaceuticals, Inc. is a pharmaceutical company focused on the development of combination therapies for neurological disorders[@noah_pharma]. The MAR polypill represents their approach to Alzheimer's disease through multi-target combination therapy, leveraging the synergistic potential of multiple established agents.

The company's focus on fixed-dose combinations aligns with broader trends in CNS drug development emphasizing polypharmacology and pathway crosstalk[@fixed_dose_combo].

Trial Design

Phase 2 Estimation Study

This is a Phase 2 estimation study — designed to estimate the magnitude of treatment effect across multiple endpoints, not to definitively establish efficacy. Phase 2 estimation studies typically inform Phase 3 sample size calculations and confirmatory trial design.

The triple-blind design (participant, care provider, and investigator blinded) represents a particularly rigorous blinding approach, minimizing bias in both subjective endpoint assessments and objective measures.

Study Structure

Randomization (1:1)
|
+---> MAR Active 0.6g tablet (QD or as directed)
| |
| v
| Double-blind treatment period
| |
+---> MAR Placebo 0.6g tablet
|
v
Placebo-controlled observation

Inclusion Criteria (Expected)

Based on the trial design and endpoints, expected inclusion criteria include:

• Age: 50-85 years
• Diagnosis: Very mild to severe Alzheimer's Disease (clinical diagnosis)
• CDR-SB: ≥ 3.0 (Clinical Dementia Rating — Sum of Boxes)
• MMSE-2: 8-24 (Mini-Mental State Examination, 2nd Edition)
• Stable medications: Concomitant AD medications (cholinesterase inhibitors, memantine) must be stable
• Caregiver availability: Study requires informant/caregiver participation

Exclusion Criteria (Expected)

• Significant neurological conditions other than AD
• Major psychiatric disorders (depression, bipolar, schizophrenia)
• Recent stroke or cerebrovascular events
• Contraindications to any polypill component
• Participation in other clinical trials

Endpoints

Primary Endpoints

The trial uses a multi-domain endpoint approach assessing cognitive, functional, and global measures[@nct06597058]:

| Endpoint | Instrument | Description |
|----------|------------|-------------|
| CDR-GS | Clinical Dementia Rating — Global Score | Global dementia severity |
| CDR-SB | Clinical Dementia Rating — Sum of Boxes | Sum of 6 domain scores (0-18 scale) |
| MMSE-2 | Mini-Mental State Examination 2nd Edition | Global cognitive function (0-30) |
| ADAS-COG | Alzheimer's Disease Assessment Scale — Cognitive Subscale | Standardized cognitive assessment |
| ADCS-ADL | Alzheimer's Disease Cooperative Study — ADL | Daily living activities |
| CGI-I | Clinical Global Impressions — Improvement | Investigator-rated global improvement |
| CGI-S | Clinical Global Impressions — Severity | Investigator-rated global severity |

Safety Endpoints

| Endpoint | Monitoring |
|----------|------------|
| TEAEs | Treatment-emergent adverse events |
| SAEs | Serious adverse events |
| AEs | General adverse event monitoring |

Clinical Outcome Measures

Clinical Dementia Rating (CDR)

The CDR is a standardized instrument assessing six domains of cognitive and functional performance:

The CDR-GS provides an overall staging score (0 = normal, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe), while the CDR-SB provides a continuous measure sensitive to change in early stages.

MMSE-2

The Mini-Mental State Examination, Second Edition is a brief 30-point screening test assessing:

• Orientation (time and place)
• Registration
• Attention and calculation
• Recall
• Language
• Visual construction

ADAS-COG

The ADAS-COG is the gold-standard cognitive outcome measure in AD clinical trials, assessing:

• Word recall
• Naming objects and fingers
• Following commands
• Constructional praxis
• Ideational praxis
• Orientation
• Word recognition
• Remembering test instructions

ADCS-ADL

The ADCS-ADL assesses functional abilities through caregiver/informant report, covering:

• Basic activities (eating, dressing, bathing)
• Instrumental activities (shopping, cooking, managing finances)
• Communication abilities

Polypill Mechanism

Fixed-Dose Combination Strategy

The MAR polypill is formulated as a 0.6g tablet containing multiple active pharmaceutical ingredients in a fixed-dose combination. The specific drug combination is proprietary, but polypill strategies for Alzheimer's disease typically include agents targeting:

1. Neurotransmitter Enhancement

• Acetylcholinesterase inhibitors: Enhance cholinergic transmission by inhibiting acetylcholinesterase (similar to [donepezil](/therapeutics/donepezil-aricept), [rivastigmine](/therapeutics/rivastigmine-exelon)))
• Glutamate modulation: NMDA receptor modulation (similar to [memantine](/therapeutics/memantine))

2. Vascular and Metabolic Support

• Antihypertensives: Address vascular contributions to cognitive decline
• Statins: Lipid-lowering with potential neuroprotective effects
• Antidiabetic agents: Address insulin resistance in AD (see [GLP-1 agonists in AD](/therapeutics/glp-1-receptor-agonists-neurodegeneration))

3. Neuroprotection

• Antioxidants: Free radical scavenging (similar to [vitamin E](/therapeutics/vitamin-e-parkinsons))
• Anti-inflammatory agents: Modulating neuroinflammation

Multi-Target Synergy

The combination of multiple agents in a single pill enables:

• Synergistic targeting: Different pathways addressed simultaneously
• Dose optimization: Each component at effective but tolerable doses
• Adherence improvement: Single pill vs. multiple medications
• Broad-spectrum coverage: More comprehensive disease modification

Alzheimer's Disease Background

Disease Overview

Alzheimer's Disease is the most common cause of dementia, affecting an estimated 6.7 million Americans aged 65 and older[@ad_epidemiology]. The disease is characterized by:

• Extracellular amyloid plaques: Accumulation of amyloid-beta (Aβ) peptides derived from [amyloid precursor protein (APP)](/genes/app) processing
• Intracellular neurofibrillary tangles: Aggregates of hyperphosphorylated [tau protein](/proteins/mapt-protein)
• Progressive neuronal loss: Particularly in hippocampus, entorhinal cortex, and association cortices
• Neuroinflammation: Microglial activation and astrocyte reactivity
• Synaptic dysfunction: Early loss of synapses correlating with cognitive decline

Treatment Landscape

The current AD treatment landscape includes:

Symptomatic therapies:

• [Acetylcholinesterase inhibitors](/therapeutics/cholinesterase-inhibitors-alzheimers) (donepezil, rivastigmine, galantamine)
• [NMDA receptor antagonists](/therapeutics/memantine) (memantine)

• [Anti-amyloid monoclonal antibodies](/therapeutics/anti-amyloid-antibodies) (lecanemab, donanemab)

Expected Outcomes

Potential Scenarios

Positive signals:

• Statistically significant separation from placebo on multiple cognitive endpoints
• Dose-response relationship evident
• Favorable safety profile supporting continued development
• Biomarker trends suggesting disease modification

• Small sample size (103) may limit statistical power
• Heterogeneity of AD patient population
• Confounding by background medications
• Regulatory pathway for fixed-dose combinations

Clinical Implications

If the MAR polypill demonstrates efficacy:

Cross-References

Related Mechanism Pages

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology-alzheimers)
• [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation-alzheimers)
• [Neurotransmission in Alzheimer's Disease](/mechanisms/neurotransmission-alzheimers)
• [Cholinergic System Deficits](/mechanisms/cholinergic-deficits-alzheimers)

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Clinical Trials](/diseases/alzheimers-disease-clinical-trials)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

Related Treatment Pages

• [Donepezil (Aricept)](/therapeutics/donepezil-aricept)
• [Memantine](/therapeutics/memantine)
• [Combination Therapy Approaches](/therapeutics/combination-therapy-alzheimers)
• [Anti-Amyloid Antibodies](/therapeutics/anti-amyloid-antibodies)

Related Trial Pages

• [Lecanemab Phase 3 CLARITY-AD](/clinical-trials/lecanemab-phase-3)
• [Donanemab Trailblazer-ALZ 2](/clinical-trials/donanemab-trailblazer-alz2)
• [AMDX-2011P Phase 2 AD](/clinical-trials/amdx-2011p-alzheimers-phase-2)
• [Semaglutide EVOKE Plus AD (NCT04777409)](/clinical-trials/semaglutide-evoke-plus-ad-nct04777409)
• [MK-1167 Phase 2 AD (NCT06721156)](/clinical-trials/mk-1167-merck-phase-2-ad-nct06721156)

See Also

Therapeutic Strategies

• [Disease-Modifying Therapies for AD](/therapeutics/disease-modifying-therapies)
• [Symptomatic Treatments for AD](/therapeutics/symptomatic-treatments)
• [Prevention and Risk Reduction](/therapeutics/prevention-risk-reduction)

Research Resources

• [Alzheimer's Association](https://www.alz.org)
• [Alzheimer's Therapeutic Research Institute](https://www.alzheimerstrials.org)
• [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597058)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

External Links

• [ClinicalTrials.gov: NCT06597058](https://clinicaltrials.gov/study/NCT06597058)
• [Noah Pharmaceuticals](https://noahpharmaceuticals.com)
• [Alzheimer's Association](https://www.alz.org)
• [Alzheimer's Disease Facts and Figures](https://www.alz.org/alzheimers-dementia/facts-figures)

References